{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:26Z","timestamp":1793296106368,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Postdoctoral Foundation from the Ministry of Human Resources and Social Security of China","award":["110215901"],"award-info":[{"award-number":["110215901"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15086-9","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:32:52Z","timestamp":1761298372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yibin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huitang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongchong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"2","key":"15086_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","volume":"67","author":"P Bertuccio","year":"2017","unstructured":"Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global trends and predictions in hepatocellular carcinoma mortality. J HEPATOL. 2017;67(2):302\u20139.","journal-title":"J HEPATOL"},{"issue":"3","key":"15086_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-CANCER J CLIN. 2024;74(3):229\u201363.","journal-title":"CA-CANCER J CLIN"},{"issue":"10360","key":"15086_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"issue":"4","key":"15086_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. NAT REV GASTRO HEPAT. 2023;20(4):203\u201322.","journal-title":"NAT REV GASTRO HEPAT"},{"issue":"1","key":"15086_CR5","first-page":"188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. BBA-REV CANCER. 2020;1874(1):188391.","journal-title":"BBA-REV CANCER"},{"issue":"4","key":"15086_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. NAT REV MOL CELL BIO. 2021;22(4):266\u201382.","journal-title":"NAT REV MOL CELL BIO"},{"issue":"5","key":"15086_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. NAT REV CLIN ONCOL. 2021;18(5):280\u201396.","journal-title":"NAT REV CLIN ONCOL"},{"issue":"7","key":"15086_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. NAT REV CANCER. 2022;22(7):381\u201396.","journal-title":"NAT REV CANCER"},{"issue":"19","key":"15086_CR9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41388-023-02665-y","volume":"42","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Xiong L, Wei T, Liu Q, Yan L, Chen J, Dai L, Shi L, Zhang W, Yang J, et al. Hypoxia-responsive PPARGC1A\/BAMBI\/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. Oncogene. 2023;42(19):1509\u201323.","journal-title":"Oncogene"},{"key":"15086_CR10","doi-asserted-by":"publisher","first-page":"103270","DOI":"10.1016\/j.redox.2024.103270","volume":"75","author":"K Zeng","year":"2024","unstructured":"Zeng K, Huang N, Liu N, Deng X, Mu Y, Zhang X, Zhang J, Zhang C, Li Y, Li Z. LACTB suppresses liver cancer progression through regulation of ferroptosis. REDOX BIOL. 2024;75:103270.","journal-title":"REDOX BIOL"},{"issue":"7","key":"15086_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","volume":"19","author":"AJ Friedmann","year":"2019","unstructured":"Friedmann AJ, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. NAT REV CANCER. 2019;19(7):405\u201314.","journal-title":"NAT REV CANCER"},{"issue":"1","key":"15086_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. SIGNAL TRANSDUCT TAR. 2020;5(1):108.","journal-title":"SIGNAL TRANSDUCT TAR"},{"issue":"12","key":"15086_CR13","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/cac2.12363","volume":"42","author":"X Zheng","year":"2022","unstructured":"Zheng X, Wang Q, Zhou Y, Zhang D, Geng Y, Hu W, Wu C, Shi Y, Jiang J. N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA. CANCER COMMUN. 2022;42(12):1347\u201366.","journal-title":"CANCER COMMUN"},{"key":"15086_CR14","doi-asserted-by":"publisher","first-page":"103087","DOI":"10.1016\/j.redox.2024.103087","volume":"71","author":"H Li","year":"2024","unstructured":"Li H, Yu K, Hu H, Zhang X, Zeng S, Li J, Dong X, Deng X, Zhang J, Zhang Y. METTL17 coordinates ferroptosis and tumorigenesis by regulating mitochondrial translation in colorectal cancer. REDOX BIOL. 2024;71:103087.","journal-title":"REDOX BIOL"},{"issue":"12","key":"15086_CR15","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1038\/s41418-023-01234-w","volume":"30","author":"S Yuan","year":"2023","unstructured":"Yuan S, Xi S, Weng H, Guo MM, Zhang JH, Yu ZP, Zhang H, Yu Z, Xing Z, Liu MY, et al. YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer. CELL DEATH DIFFER. 2023;30(12):2477\u201390.","journal-title":"CELL DEATH DIFFER"},{"issue":"2","key":"15086_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. NAT MED. 2016;22(2):128\u201334.","journal-title":"NAT MED"},{"issue":"1","key":"15086_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J HEMATOL ONCOL. 2020;13(1):104.","journal-title":"J HEMATOL ONCOL"},{"issue":"1","key":"15086_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13046-023-02855-2","volume":"42","author":"K Wang","year":"2023","unstructured":"Wang K, Jiang X, Jiang Y, Liu J, Du Y, Zhang Z, Li Y, Zhao X, Li J, Zhang R. EZH2-H3K27me3-mediated Silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A. J EXP CLIN CANC RES. 2023;42(1):320.","journal-title":"J EXP CLIN CANC RES"},{"issue":"1","key":"15086_CR19","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1038\/s41467-022-30105-0","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Qu J, Qi Y, Duan Y, Huang YW, Zhou Z, Li P, Yao J, Huang B, Zhang S, et al. EZH2 engages TGF\u03b2 signaling to promote breast cancer bone metastasis via integrin \u03b21-FAK activation. NAT COMMUN. 2022;13(1):2543.","journal-title":"NAT COMMUN"},{"issue":"1","key":"15086_CR20","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","volume":"15","author":"P Romero","year":"2024","unstructured":"Romero P, Richart L, Aflaki S, Petitalot A, Burton M, Michaud A, Masliah-Planchon J, Kuhnowski F, Le Cam S, Bali\u00f1as-Gavira C, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 Inhibition. NAT COMMUN. 2024;15(1):3452.","journal-title":"NAT COMMUN"},{"issue":"23","key":"15086_CR21","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1158\/0008-5472.CAN-23-1475","volume":"83","author":"Y Huang","year":"2023","unstructured":"Huang Y, Durall RT, Luong NM, Hertzler HJ, Huang J, Gokhale PC, Leeper BA, Persky NS, Root DE, Anekal PV, et al. EZH2 cooperates with BRD4-NUT to drive NUT carcinoma growth by Silencing key tumor suppressor genes. CANCER RES. 2023;83(23):3956\u201373.","journal-title":"CANCER RES"},{"issue":"20","key":"15086_CR22","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/0008-5472.CAN-20-0458","volume":"80","author":"X Zong","year":"2020","unstructured":"Zong X, Wang W, Ozes A, Fang F, Sandusky GE, Nephew KP. EZH2-Mediated downregulation of the tumor suppressor DAB2IP maintains ovarian cancer stem cells. CANCER RES. 2020;80(20):4371\u201385.","journal-title":"CANCER RES"},{"issue":"33","key":"15086_CR23","doi-asserted-by":"publisher","first-page":"e1991957176","DOI":"10.1073\/pnas.2303010120","volume":"120","author":"L Liu","year":"2023","unstructured":"Liu L, Xiao B, Hirukawa A, Smith HW, Zuo D, Sanguin-Gendreau V, McCaffrey L, Nam AJ, Muller WJ. Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways. P NATL ACAD SCI USA. 2023;120(33):e1991957176.","journal-title":"P NATL ACAD SCI USA"},{"key":"15086_CR24","doi-asserted-by":"publisher","first-page":"216143","DOI":"10.1016\/j.canlet.2023.216143","volume":"560","author":"P Kaur","year":"2023","unstructured":"Kaur P, Verma S, Kushwaha PP, Gupta S. EZH2 and NF-\u03baB: A context-dependent crosstalk and transcriptional regulation in cancer. CANCER LETT. 2023;560:216143.","journal-title":"CANCER LETT"},{"key":"15086_CR25","doi-asserted-by":"publisher","first-page":"216706","DOI":"10.1016\/j.canlet.2024.216706","volume":"586","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S. EZH2-mediated development of therapeutic resistance in cancer. CANCER LETT. 2024;586:216706.","journal-title":"CANCER LETT"},{"issue":"10","key":"15086_CR26","first-page":"6662","volume":"7","author":"TY Fan","year":"2014","unstructured":"Fan TY, Wang H, Xiang P, Liu YW, Li HZ, Lei BX, Yu M, Qi ST. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. INT J CLIN EXP PATHO. 2014;7(10):6662\u201370.","journal-title":"INT J CLIN EXP PATHO"},{"issue":"2","key":"15086_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31(2):286\u201399.","journal-title":"Cancer Cell"},{"issue":"2","key":"15086_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185\u201397.","journal-title":"Cancer Cell"},{"issue":"8039","key":"15086_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","volume":"635","author":"AE Schade","year":"2024","unstructured":"Schade AE, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Gardner A, Loi P, Xu Y, Nguyen V, Mastellone GM, et al. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of Involution. Nat. 2024;635(8039):755\u201363.","journal-title":"Nature"},{"issue":"24","key":"15086_CR30","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1182\/blood.2024026534","volume":"145","author":"V Nguyen","year":"2025","unstructured":"Nguyen V, Namba H, Porter H, Shlyueva D, Lopez E, Melcher A, B\u00e9guelin W, Melnick AM, Helin K. Synergistic antitumor effect of combined EZH2 and DOT1L Inhibition in B-cell lymphoma. Blood. 2025;145(24):2873\u201386.","journal-title":"Blood"},{"issue":"11","key":"15086_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. LANCET ONCOL. 2020;21(11):1423\u201332.","journal-title":"LANCET ONCOL"},{"issue":"11","key":"15086_CR32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. LANCET ONCOL. 2020;21(11):1433\u201342.","journal-title":"LANCET ONCOL"},{"issue":"24","key":"15086_CR33","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich ML, Athar M, Ferguson JR, Varambally S. EZH2-Targeted therapies in cancer: hype or a reality. CANCER RES. 2020;80(24):5449\u201358.","journal-title":"CANCER RES"},{"issue":"1","key":"15086_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7150\/ijbs.8.59","volume":"8","author":"KH Yoo","year":"2012","unstructured":"Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. INT J BIOL SCI. 2012;8(1):59\u201365.","journal-title":"INT J BIOL SCI"},{"issue":"39","key":"15086_CR35","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","volume":"40","author":"SH Park","year":"2021","unstructured":"Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond polycomb: EZH2 functions in prostate cancer. Oncogene. 2021;40(39):5788\u201398.","journal-title":"Oncogene"},{"key":"15086_CR36","doi-asserted-by":"publisher","unstructured":"Yu W, Liu N, Song X, et al. EZH2: An Accomplice of Gastric Cancer. Cancers (Basel). 2023;15(2):425. Published 2023 Jan 9. https:\/\/doi.org\/10.3390\/cancers15020425.","DOI":"10.3390\/cancers15020425"},{"issue":"1","key":"15086_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-023-00405-2","volume":"12","author":"B Wang","year":"2023","unstructured":"Wang B, Liu Y, Liao Z, Wu H, Zhang B, Zhang L. EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies. EXP HEMATOL ONCOL. 2023;12(1):52.","journal-title":"EXP HEMATOL ONCOL"},{"issue":"1","key":"15086_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, Li B. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J HEMATOL ONCOL. 2019;12(1):34.","journal-title":"J HEMATOL ONCOL"},{"key":"15086_CR39","doi-asserted-by":"publisher","first-page":"174397","DOI":"10.1016\/j.ejphar.2021.174397","volume":"909","author":"J Quan","year":"2021","unstructured":"Quan J, Bode AM, Luo X. ACSL family: the regulatory mechanisms and therapeutic implications in cancer. EUR J PHARMACOL. 2021;909:174397.","journal-title":"EUR J PHARMACOL"},{"issue":"1","key":"15086_CR40","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/s41467-021-22471-y","volume":"12","author":"A Beatty","year":"2021","unstructured":"Beatty A, Singh T, Tyurina YY, Tyurin VA, Samovich S, Nicolas E, Maslar K, Zhou Y, Cai KQ, Tan Y, et al. Ferroptotic cell death triggered by conjugated linolenic acids is mediated by ACSL1. NAT COMMUN. 2021;12(1):2244.","journal-title":"NAT COMMUN"},{"issue":"1","key":"15086_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng CS, Chen L. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J HEMATOL ONCOL. 2024;17(1):130.","journal-title":"J HEMATOL ONCOL"},{"key":"15086_CR42","doi-asserted-by":"crossref","unstructured":"Hoy SM. Tazemetostat: first approval. DRUGS. 2020;80(5):513\u201321.","DOI":"10.1007\/s40265-020-01288-x"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15086-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15086-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15086-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:32:53Z","timestamp":1761298373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15086-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15086"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15086-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments were performed following the policies of the Animal Ethics Committee of AffiliatedCancer Hospital and Institute of Guangzhou Medical University and conducted in strict compliance with ethical guidelines. Following the Declaration of Helsinki, this study acquired the approval by the Medical Ethics Committee of AffiliatedCancer Hospital and Institute of Guangzhou Medical University. Informed consent was acquired from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1638"}}